Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Misconduct Fine In Actos Suit Could Alter Future Generic Challenges

Executive Summary

Generic drug manufacturers may be more cautious in challenging the validity of a brand name company's patent after an appeals court affirmed that Takeda was entitled to $16.8 million in attorneys fees in litigation over its diabetes drug Actos
Advertisement

Related Content

180-Day Exclusivity Decision On Acarbose Illustrates Importance Of ANDA Quality
Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops
Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops
Advertisement
UsernamePublicRestriction

Register

PS050477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel